Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

B Liu, M Li, Z Zhou, X Guan, Y Xiang - Journal of autoimmunity, 2020 - Elsevier
The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …

Tumor necrosis factor α and regulatory T cells in oncoimmunology

BL Salomon, M Leclerc, J Tosello, E Ronin… - Frontiers in …, 2018 - frontiersin.org
Tumor necrosis factor α (TNF) is a potent pro-inflammatory cytokine that has deleterious
effect in some autoimmune diseases, which led to the use of anti-TNF drugs in some of …

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease

F Malard, XJ Huang, JPY Sim - Leukemia, 2020 - nature.com
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic
hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and …

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

MA Schroeder, HJ Khoury, M Jagasia, H Ali… - Blood …, 2020 - ashpublications.org
Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell
transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to …

[HTML][HTML] Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review

Y Fløisand, VL Lazarevic, J Maertens… - Biology of Blood and …, 2019 - Elsevier
Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative in patients with
hematologic malignancies but carries a significant risk of graft-versus-host disease (GVHD) …

Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology

A Saad, M de Lima, S Anand, VR Bhatt… - Journal of the National …, 2020 - jnccn.org
Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor
cells into patients with hematologic disorders with the goal of re-establishing normal …

Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape

RM Shapiro, JH Antin - Expert Review of Hematology, 2020 - Taylor & Francis
Introduction The traditional therapeutic modalities to manage SR-acute GVHD have focused
on the inhibition of the alloreactive T-cell response, while in the setting of SR-chronic GVHD …

The effect of TNF-α on regulatory T cell function in graft-versus-host disease

A Mancusi, S Piccinelli, A Velardi, A Pierini - Frontiers in immunology, 2018 - frontiersin.org
FoxP3+ regulatory T cells (Tregs) are a subset of CD4+ T cells that can suppress
proliferation and effector functions of T cells, B cells, NK cells, and antigen-presenting cells …

Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors

X Li, SKP Lau, PCY Woo - Experimental Biology and …, 2020 - journals.sagepub.com
The revolutionary success of biologic agents in treating various malignant and autoimmune
conditions has been met with increased risk of opportunistic infections due to perturbations …

Ruxolitinib in children with steroid‐refractory acute graft‐versus‐host disease: A retrospective multicenter study of the pediatric group of SFGM‐TC

L Laisne, B Neven, JH Dalle… - Pediatric Blood & …, 2020 - Wiley Online Library
Background We conducted a national multicenter retrospective study in France to evaluate
the efficacy and tolerance of ruxolitinib in children with steroid‐refractory acute graft‐versus …